製品の概要

  • 製品名Anti-IL13 antibody [B-B13]
    IL13 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [B-B13] to IL13
  • 特異性This antibody binds with high affinity and neutralizes both natural and recombinant human IL13.
  • アプリケーション適用あり: ELISA, ELISpot, Neutralisingmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Recombinant full length protein (Human)

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab25037 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ELISA Use at an assay dependent dilution.
ELISpot Use at an assay dependent dilution.
Neutralising Use at an assay dependent dilution. In vitro and intracellular.

ターゲット情報

  • 機能Cytokine (PubMed:8096327, PubMed:8097324). Inhibits inflammatory cytokine production (PubMed:8096327). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). May be critical in regulating inflammatory and immune responses (PubMed:8096327, PubMed:8097324). Positively regulates IL31RA expression in macrophages.
  • 関連疾患Allergic rhinitis
  • 配列類似性Belongs to the IL-4/IL-13 family.
  • 細胞内局在Secreted.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Allergic rhinitis antibody
    • ALRH antibody
    • BHR1 antibody
    • Bronchial hyperresponsiveness 1 (bronchial asthma) antibody
    • IL 13 antibody
    • IL-13 antibody
    • Il13 antibody
    • IL13_HUMAN antibody
    • Interleukin 13 antibody
    • Interleukin-13 antibody
    • MGC116786 antibody
    • MGC116788 antibody
    • MGC116789 antibody
    • NC30 antibody
    • P600 antibody
    see all

Anti-IL13 antibody [B-B13] (ab25037) 使用論文

ab25037 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab25037.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"